CME Sues CFTC to Overturn Kalshi’s U.S. Bitcoin Perpetual Futures Approval
The exchange argues the product should be treated as a Dodd-Frank swap and says the agency skipped required analysis.
CME Group filed suit against the Commodity Futures Trading Commission to vacate the agency’s end-of-May approval of Kalshi’s U.S. perpetual futures contracts, including a bitcoin perpetual. The case turns on whether the CFTC can treat a perpetual as a futures contract rather than a Dodd-Frank “swap,” a classification that changes the regulatory rulebook for U.S.-linked crypto perps.
Key Takeaways
- CME Group is asking a court to vacate the CFTC’s end-of-May approval of Kalshi’s perpetual futures contracts and the related self-certified products.
- The lawsuit alleges the CFTC’s approval process violated Dodd-Frank and failed to independently analyze whether the bitcoin perpetual fits the law.
- CME argues Kalshi’s bitcoin perpetual should be regulated as a Dodd-Frank “swap,” not a “future,” because that label changes requirements for issuers and participants.
- The CFTC also issued a same-day no-action letter to Coinbase that was described as potentially opening a route to list perps via an offshore intermediary.
CME Takes the CFTC to Court Over Kalshi’s U.S. Bitcoin Perp
CME Group sued the Commodity Futures Trading Commission in June, asking a court to unwind the agency’s end-of-May approval of Kalshi’s first U.S. perpetual futures contracts. The relief CME is seeking is blunt: vacate the approval and the self-certified products tied to it.
The timing matters. The suit landed a day after outgoing CME CEO Terry Duffy said the company would file, turning what could have been a quiet regulatory disagreement into a direct court test of the CFTC’s approach to a product class that dominates offshore crypto derivatives.
It is also an unusual escalation in U.S. market structure terms. A major exchange is challenging its primary regulator’s handling of a newly approved derivatives product, and doing it in a way that forces the court to look at the legal plumbing, not the marketing.
The Core Dispute: Are Perpetual Futures Actually Dodd-Frank Swaps?
Perpetual futures, or “perps,” are futures-style contracts that typically do not expire and are kept aligned with spot through periodic payments often referred to as funding. That “no expiry” feature is exactly what CME is trying to turn into a legal wedge.
CME’s position is that Kalshi’s bitcoin perpetual is not properly a futures contract at all. It should be treated as a “swap” under Dodd-Frank, which is a defined category in the statute and comes with different regulatory implications for how products are listed and what requirements apply to the firms offering them and the participants trading them.
What stands out here is how much of the U.S. crypto perps conversation collapses into this single classification question. If the CFTC can treat a perpetual as a futures contract, the path to U.S.-regulated perps looks more like an extension of existing exchange-listed derivatives. If perps are forced into the swap bucket, the compliance and listing pathway can change materially, and the burden shifts to a different set of rules.
CME has also framed perps as a competitive threat to its long-dated futures products. That is not a side note. It is the economic incentive behind the legal argument, and it explains why this fight is happening now, right as U.S.-regulated venues are probing how far they can push the derivatives envelope.
CME’s Procedural Attack: Alleged Dodd-Frank Violations and a ‘Rubber-Stamp’ Approval
CME’s sharpest blade is procedural. The complaint argues the CFTC did not do the work Dodd-Frank requires when confronted with a novel product that may fit a defined statutory category.
CME’s lawsuit states: “The CFTC did not engage in its own analysis of whether its approval of Kalshi’s Bitcoin perpetual as a future is consistent with law,” and adds: “The CFTC did not even mention the relevant Dodd-Frank provision defining 'swap.' Indeed, the word 'swap' appears nowhere in the Order.”
That is a very specific allegation. It is not just “we disagree with the outcome.” It is “the agency did not grapple with the controlling definition.” CME also claims the CFTC “rubberstamped Kalshi's application,” which is the kind of phrasing designed to pull the court toward process failures rather than technical debates about product design.
The second-order effect traders should care about is that procedural arguments can scale beyond this one product. If a court buys the idea that the CFTC must explicitly engage the swap definition when approving perps as futures, that logic can spill into how other novel derivatives are self-certified or approved going forward.
There is also real legal gray area in the background. Former Starkware General Counsel Katherine Kirkpatrick Bos said in an email, “Future is not defined anywhere, whereas swap was defined by Dodd-Frank.” She added that the CFTC has discretion to categorize novel products with characteristics of a future as futures rather than swaps. On X, she said there is “no clear precedent” on “future delivery” being a requirement for a future.
That ambiguity cuts both ways. CME is arguing the lack of expiry is determinative. The counterpoint is that the statute’s asymmetry, swap defined and future not defined, may leave the CFTC room to classify.
Signals Traders Should Track as the U.S. Perps Rulebook Gets Tested
The near-term market signal is not price. It is process.
First, watch for any court action on CME’s request to vacate the CFTC’s end-of-May approval of Kalshi’s perpetual futures and the related self-certified products. An injunction, expedited briefing, or early dismissal posture would each send a different message about how seriously the court is taking the procedural claims.
Second, monitor whether the CFTC publicly clarifies or defends its classification approach for perps as futures versus swaps in response to the lawsuit. CME’s complaint is explicitly about the absence of swap-definition engagement. Any agency response that fills that gap changes the informational playing field.
Third, track follow-on moves by other venues seeking to list U.S.-regulated perps, especially anything tied to the Coinbase no-action posture described in the same end-of-May window. The details of that letter and the “offshore intermediary” structure are not provided here, but the sequencing matters. It suggests the regulator’s posture on perps may be broader than a single Kalshi approval.
Finally, keep an eye on any shift in CFTC guidance or enforcement posture around self-certification for novel derivatives after this challenge. CME is not only contesting the label. It is contesting the pathway.
This Is a Market-Structure Fight Disguised as a Definitions Fight
I read this as CME trying to reset the regulatory pathway for U.S.-listed crypto perps by forcing a court to scrutinize whether the CFTC can treat a perpetual as a futures contract instead of a Dodd-Frank swap. The headline is “swaps vs futures,” but the real object is control over how perps get productized inside the U.S. rulebook.
The pattern worth noting is that CME is leaning hardest on procedure, not just classification. The quotes in the complaint are aimed at a court-friendly narrative: the agency did not do its own analysis, did not even mention the swap definition, and “rubberstamped” the application. If that framing sticks, it does not just threaten Kalshi’s approval. It pressures the CFTC to show its work the next time a designated contract market tries to self-certify something that looks like a perp.
There are two clean scenarios.
Scenario A: the court signals early that the procedural claims have teeth. Confirmation would look like expedited handling, a meaningful order addressing the absence of swap-definition analysis, or any relief that pauses or threatens the approval CME wants vacated. In that world, the immediate impact is uncertainty around whether perps can be scaled as futures products in the U.S. without a more explicit legal rationale. The second-order impact is that other venues may slow-roll listings until the classification logic is clearer.
Scenario B: the court is unreceptive, either by dismissing early or by treating the CFTC’s discretion as broad enough given that “future” is not defined in Dodd-Frank while “swap” is. Invalidation would look like the court declining to engage the swap-definition argument as a gating issue, or otherwise signaling that the agency can categorize novel products with futures-like characteristics as futures. In that world, the Kalshi approval becomes a precedent in practice, and the same-day Coinbase no-action posture starts to matter more because it hints at a wider opening for U.S.-linked perp access, even if the exact constraints remain unclear.
My base case from the facts in hand is that this stays a process fight longer than people expect. CME is not arguing about funding mechanics or contract specs in the excerpt we have. It is arguing the CFTC skipped the statutory definition it needed to confront. The thesis is confirmed if the court forces the CFTC to explicitly justify, in Dodd-Frank terms, why a bitcoin perpetual can be treated as a futures contract rather than a swap.
